Diabetic macular oedema / Diabetic retinopathy
PRP DVF: The effect of the distribution of panretinal photocoagulation (PRP) laser on driving visual fields in people with diabetes
Principal Investigator:
Dr Christine Kiire
Research summary
Maintaining adequate vision for safe driving is a common concern for people with diabetic eye disease. One of the typical treatments for severe levels of diabetic eye disease is panretinal photocoagulation (PRP) laser treatment. Although PRP laser has been shown to halve the risk of severe vision loss and help to stabilise diabetic eye disease in the long term, it causes laser scars that can affect peripheral vision. In addition to visual acuity standards (reading a number plate from 20m), the Driving Licence and Vehicle Agency (DVLA) has set out standards for the level of peripheral vision required to hold a driving licence, and people who have had PRP laser undergo visual field testing to confirm whether they meet this standard. The risk of failing this test is a major concern for people with diabetes who wish to drive. PRP laser treatments vary widely in the distribution of the laser scars created on the retina. Reasons for this include differences in the severity of the disease, the type of laser being used, the preferred settings of the laser operator, the location of the most severely affected parts of the retina, and time since the laser treatment. Although some small studies in the UK have shown encouraging results about people with diabetes retaining driving vision in the short-term after PRP laser, they have not assessed how the distribution of PRP laser scars impact this. This is a pilot study which aims to provide new data on how different extents of PRP laser impact driving visual fields and subjective visual function in people with diabetes. The results of this study will help with the development of a protocol for a larger, more in-depth study of the impact of established eye treatments for diabetic retinopathy on peripheral vision, including driving vision.
https://studies.ouh.nhs.uk/project_detail/11061/
IRAS number
344298
VOYAGER Study: Real-World, long-term data collection to gain clinical insights into Roche ophthalmology products
Eye condition/Study type:
Neovascular age-related macular degeneration (wet AMD) or Diabetic macular oedema
Principal Investigator:
Miss Christine Kiire
This study will explore long-term effectiveness, safety, clinical insights, treatment patterns, and factors driving the treatment decisions among patients being treated with specified Roche ophthalmology products approved in retinal indications in real-world, routine clinical practice.
https://studies.ouh.nhs.uk/project_detail/9760/
Contact ERGO@ouh.nhs.uk if you have any questions.
NOT RECRUITING / IN FOLLOW UP
BREYE: A phase 1b open-label, dose-escalating study evaluating the safety, tolerability, pharmacokinetics and early signs of biological activity of Danegaptide following oral administration in subjects with Diabetic Macular Oedema (DME)
Eye condition/Study type:
Diabetic Macular Oedema (DME)
Principal Investigator:
Miss Christine Kiire
This is a multicentre, sequential-group, open-label, uncontrolled, dose-escalating Phase 1b study assessing the safety, tolerability, pharmacokinetics (PK), metabolite profile, and early signs of biological activity following oral administration of danegaptide in participants diagnosed with Diabetic Macular Oedema. A total of 4 cohorts are planned to explore escalating doses (75 and 150 mg) and/or different dosing frequencies (once and twice daily) of danegaptide. Cohort 1: 75 mg once daily; Cohort 2: 75 mg twice daily; Cohort 3: 150 mg once daily; Cohort 4: 150 mg twice daily.
https://studies.ouh.nhs.uk/project_detail/9529/
Currently recruiting. If interested, please contact via email ERGO@ouh.nhs.uk
NOT RECRUITING / IN FOLLOW UP